Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | EDNRB | P24530 | 4/20 | 0.40 |
| ▸ | EDNRA | P25101 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754794 | 0.81 | TSHR (0.50) | POLBTSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL25754797 | 0.79 | GAA (0.50) | POLBMAPTTSHRKMT2AMEN1 | |
| SCHEMBL23846666 | 0.78 | KMT2A (0.53) | MAPTTSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL25754766 | 0.78 | SMN1; SMN2 (0.53) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL25754833 | 0.75 | PKM (0.54) | POLBMAPTTSHRKMT2AMEN1 | |
| SCHEMBL25754837 | 0.75 | MAPT (0.58) | POLBMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL25754796 | 0.75 | SLC22A12 (0.52) | MAPTTSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL11508785 | 0.74 | PKM (0.58) | POLBMAPTTSHRKMT2AMEN1 | |
| SCHEMBL3844757 | 0.73 | TSHR (0.69) | MAPTTSHRKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL25754835 | 0.72 | IDH1 (0.53) | MAPTKMT2AMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | POLB 1494/4885MAPT 89/4885BRD4 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.